Global Carbapenem-Based Antibiotics Market Research Report 2026

Carbapenem-Based Antibiotics Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Carbapenem-Based Antibiotics competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

Carbapenem-based antibiotics are a critical class of broad-spectrum beta-lactam agents used for the treatment of severe and complicated bacterial infections, most commonly supplied as sterile powder for injection or injectable formulations. They are widely indicated for severe pneumonia, sepsis, complicated intra-abdominal and urinary tract infections, and hospital-acquired infections associated with multidrug-resistant Gram-negative pathogens, and are typically managed under strict antimicrobial stewardship programs in hospital settings. The upstream supply chain includes pharmaceutical-grade beta-lactam core structures and key side-chain intermediates with complex synthesis and stringent impurity control, excipients for sterile injectables such as buffers and stabilizers, water for injection, sterile packaging components, and GMP-compliant aseptic compounding, filling, lyophilization, and quality-control equipment, all requiring robust process control and sterility assurance. Downstream customers primarily consist of general hospitals, tertiary hospitals, regional medical centers, and key specialty departments including ICUs and infectious disease units, with demand driven by centralized hospital procurement and public reimbursement systems. On an ex-factory basis, global nominal capacity for finished carbapenem-based antibiotic formulations in 2025 is estimated at approximately 742 million vials, with actual sales volume of around 596 million vials and an average global ex-factory selling price of about USD 7.9 per vial. Supported by high technical barriers in aseptic manufacturing but constrained by tender-driven pricing and intense generic competition, manufacturers typically achieve gross margins in the range of 40%–55%, reflecting an industry where compliance strength, supply reliability, and scale efficiency are the primary determinants of profitability.

From a market perspective, the hospital anti-infective segment for carbapenem-based antibiotics has reached a highly mature and tightly regulated stage. These agents are clearly positioned as essential therapies for severe and complicated infections and are commonly included in restricted-use or stewardship-controlled formularies across healthcare systems. Following patent expiration, the market has evolved into a multi-generic landscape, with competition increasingly centered on quality consistency, supply reliability, regulatory compliance, and hospital access capabilities rather than brand differentiation.

In terms of demand drivers, the persistent need to manage severe infections, the prevalence of multidrug-resistant Gram-negative pathogens, and the widespread use of invasive medical procedures continue to underpin demand. Although antimicrobial stewardship policies emphasize rational and targeted use, hospitals still rely on carbapenems in high-risk clinical settings such as intensive care, complex surgical infections, and immunocompromised patient populations, supporting their sustained importance within inpatient treatment protocols.

Looking ahead, market development is expected to focus on structural optimization and efficiency improvements rather than continued volume expansion. Hospitals are placing greater emphasis on product quality stability, batch traceability, and uninterrupted supply, which may accelerate consolidation toward manufacturers with robust aseptic production platforms and comprehensive quality systems. At the same time, the introduction of newer antibacterial agents, combination regimens, and resistance-management strategies is likely to narrow carbapenem use in certain indications, further concentrating their application in clearly defined clinical scenarios.

Against this backdrop, both growth drivers and constraints will shape the long-term outlook. Cost-containment measures such as centralized procurement, reimbursement controls, and antibiotic classification policies exert sustained pressure on pricing and utilization, while the technical and regulatory demands of sterile manufacturing increase operational complexity and exposure to upstream supply risks. For manufacturers, long-term competitiveness in the carbapenem-based antibiotic market will depend on maintaining regulatory compliance, cost discipline, and reliable supply within an increasingly controlled healthcare environment.

This report delivers a comprehensive overview of the global Carbapenem-Based Antibiotics market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Carbapenem-Based Antibiotics. The Carbapenem-Based Antibiotics market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Carbapenem-Based Antibiotics market comprehensively. Regional market sizes by Type, by Application, by Dosage Form, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Carbapenem-Based Antibiotics manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Carbapenem-Based Antibiotics Market Report

Chapter Outline

1.1 Product Definition

1.2 Carbapenem-Based Antibiotics by Type

1.2.1 Global Carbapenem-Based Antibiotics Market Value by Type: 2025 vs 2032

1.2.2 Meropenem

1.2.3 Imipenem

1.2.4 Ertapenem

1.2.5 Doripenem

1.2.6 Others

1.3 Carbapenem-Based Antibiotics by Dosage Form

1.3.1 Global Carbapenem-Based Antibiotics Market Value by Dosage Form: 2025 vs 2032

1.3.2 Sterile Powder for Injection

1.3.3 Ready-to-use or Premixed Injection

1.3.4 Others

1.4 Carbapenem-Based Antibiotics by Clinical Indication

1.4.1 Global Carbapenem-Based Antibiotics Market Value by Clinical Indication: 2025 vs 2032

1.4.2 Severe Hospital-acquired Infections

1.4.3 Drug-resistant Bacterial Infections

1.4.4 Others

1.5 Carbapenem-Based Antibiotics by Application

1.5.1 Global Carbapenem-Based Antibiotics Market Value by Application: 2025 vs 2032

1.5.2 Hospital

1.5.3 Clinic

1.5.4 Others

1.6 Global Carbapenem-Based Antibiotics Market Size Estimates and Forecasts

1.6.1 Global Carbapenem-Based Antibiotics Revenue 2021–2032

1.6.2 Global Carbapenem-Based Antibiotics Sales 2021–2032

1.6.3 Global Carbapenem-Based Antibiotics Market Average Price (2021–2032)

1.7 Assumptions and Limitations

2.1 Global Carbapenem-Based Antibiotics Sales Market Share by Manufacturers (2021–2026)

2.2 Global Carbapenem-Based Antibiotics Revenue Market Share by Manufacturers (2021–2026)

2.3 Global Carbapenem-Based Antibiotics Average Price by Manufacturers (2021–2026)

2.4 Global Key Players of Carbapenem-Based Antibiotics, Industry Ranking, 2023 vs 2024 vs 2025

2.5 Global Key Manufacturers of Carbapenem-Based Antibiotics, Manufacturing Sites and Headquarters

2.6 Global Key Manufacturers of Carbapenem-Based Antibiotics, Product Types and Applications

2.7 Global Key Manufacturers of Carbapenem-Based Antibiotics, Date of Entry into the Industry

2.8 Global Carbapenem-Based Antibiotics Market Competitive Situation and Trends

2.8.1 Global Carbapenem-Based Antibiotics Market Concentration Rate

2.8.2 The Top 5 and Top 10 Global Carbapenem-Based Antibiotics Players Market Share by Revenue

2.8.3 Global Carbapenem-Based Antibiotics Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3.1 Global Carbapenem-Based Antibiotics Market Size by Region: 2021 vs 2025 vs 2032

3.2 Global Carbapenem-Based Antibiotics Sales by Region: 2021–2032

3.2.1 Global Carbapenem-Based Antibiotics Sales by Region: 2021–2026

3.2.2 Global Carbapenem-Based Antibiotics Sales by Region: 2027–2032

3.3 Global Carbapenem-Based Antibiotics Revenue by Region: 2021–2032

3.3.1 Global Carbapenem-Based Antibiotics Revenue by Region: 2021–2026

3.3.2 Global Carbapenem-Based Antibiotics Revenue by Region: 2027–2032

3.4 North America Carbapenem-Based Antibiotics Market Facts & Figures by Country

3.4.1 North America Carbapenem-Based Antibiotics Market Size by Country: 2021 vs 2025 vs 2032

3.4.2 North America Carbapenem-Based Antibiotics Sales by Country (2021–2032)

3.4.3 North America Carbapenem-Based Antibiotics Revenue by Country (2021–2032)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Carbapenem-Based Antibiotics Market Facts & Figures by Country

3.5.1 Europe Carbapenem-Based Antibiotics Market Size by Country: 2021 vs 2025 vs 2032

3.5.2 Europe Carbapenem-Based Antibiotics Sales by Country (2021–2032)

3.5.3 Europe Carbapenem-Based Antibiotics Revenue by Country (2021–2032)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Carbapenem-Based Antibiotics Market Facts & Figures by Region

3.6.1 Asia Pacific Carbapenem-Based Antibiotics Market Size by Region: 2021 vs 2025 vs 2032

3.6.2 Asia Pacific Carbapenem-Based Antibiotics Sales by Region (2021–2032)

3.6.3 Asia Pacific Carbapenem-Based Antibiotics Revenue by Region (2021–2032)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Carbapenem-Based Antibiotics Market Facts & Figures by Country

3.7.1 Latin America Carbapenem-Based Antibiotics Market Size by Country: 2021 vs 2025 vs 2032

3.7.2 Latin America Carbapenem-Based Antibiotics Sales by Country (2021–2032)

3.7.3 Latin America Carbapenem-Based Antibiotics Revenue by Country (2021–2032)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Carbapenem-Based Antibiotics Market Facts & Figures by Country

3.8.1 Middle East and Africa Carbapenem-Based Antibiotics Market Size by Country: 2021 vs 2025 vs 2032

3.8.2 Middle East and Africa Carbapenem-Based Antibiotics Sales by Country (2021–2032)

3.8.3 Middle East and Africa Carbapenem-Based Antibiotics Revenue by Country (2021–2032)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4.1 Global Carbapenem-Based Antibiotics Sales by Type (2021–2032)

4.1.1 Global Carbapenem-Based Antibiotics Sales by Type (2021–2026)

4.1.2 Global Carbapenem-Based Antibiotics Sales by Type (2027–2032)

4.1.3 Global Carbapenem-Based Antibiotics Sales Market Share by Type (2021–2032)

4.2 Global Carbapenem-Based Antibiotics Revenue by Type (2021–2032)

4.2.1 Global Carbapenem-Based Antibiotics Revenue by Type (2021–2026)

4.2.2 Global Carbapenem-Based Antibiotics Revenue by Type (2027–2032)

4.2.3 Global Carbapenem-Based Antibiotics Revenue Market Share by Type (2021–2032)

4.3 Global Carbapenem-Based Antibiotics Price by Type (2021–2032)

5.1 Global Carbapenem-Based Antibiotics Sales by Application (2021–2032)

5.1.1 Global Carbapenem-Based Antibiotics Sales by Application (2021–2026)

5.1.2 Global Carbapenem-Based Antibiotics Sales by Application (2027–2032)

5.1.3 Global Carbapenem-Based Antibiotics Sales Market Share by Application (2021–2032)

5.2 Global Carbapenem-Based Antibiotics Revenue by Application (2021–2032)

5.2.1 Global Carbapenem-Based Antibiotics Revenue by Application (2021–2026)

5.2.2 Global Carbapenem-Based Antibiotics Revenue by Application (2027–2032)

5.2.3 Global Carbapenem-Based Antibiotics Revenue Market Share by Application (2021–2032)

5.3 Global Carbapenem-Based Antibiotics Price by Application (2021–2032)

6.1 Gland Pharma

6.1.1 Gland Pharma Company Information

6.1.2 Gland Pharma Description and Business Overview

6.1.3 Gland Pharma Carbapenem-Based Antibiotics Sales, Revenue, and Gross Margin (2021–2026)

6.1.4 Gland Pharma Carbapenem-Based Antibiotics Product Portfolio

6.1.5 Gland Pharma Recent Developments/Updates

6.2 Merck

6.2.1 Merck Company Information

6.2.2 Merck Description and Business Overview

6.2.3 Merck Carbapenem-Based Antibiotics Sales, Revenue, and Gross Margin (2021–2026)

6.2.4 Merck Carbapenem-Based Antibiotics Product Portfolio

6.2.5 Merck Recent Developments/Updates

6.3 Savior Lifetec

6.3.1 Savior Lifetec Company Information

6.3.2 Savior Lifetec Description and Business Overview

6.3.3 Savior Lifetec Carbapenem-Based Antibiotics Sales, Revenue, and Gross Margin (2021–2026)

6.3.4 Savior Lifetec Carbapenem-Based Antibiotics Product Portfolio

6.3.5 Savior Lifetec Recent Developments/Updates

6.4 Sumitomo Pharma

6.4.1 Sumitomo Pharma Company Information

6.4.2 Sumitomo Pharma Description and Business Overview

6.4.3 Sumitomo Pharma Carbapenem-Based Antibiotics Sales, Revenue, and Gross Margin (2021–2026)

6.4.4 Sumitomo Pharma Carbapenem-Based Antibiotics Product Portfolio

6.4.5 Sumitomo Pharma Recent Developments/Updates

6.5 Pfizer

6.5.1 Pfizer Company Information

6.5.2 Pfizer Description and Business Overview

6.5.3 Pfizer Carbapenem-Based Antibiotics Sales, Revenue, and Gross Margin (2021–2026)

6.5.4 Pfizer Carbapenem-Based Antibiotics Product Portfolio

6.5.5 Pfizer Recent Developments/Updates

6.6 Aurobindo Pharma

6.6.1 Aurobindo Pharma Company Information

6.6.2 Aurobindo Pharma Description and Business Overview

6.6.3 Aurobindo Pharma Carbapenem-Based Antibiotics Sales, Revenue, and Gross Margin (2021–2026)

6.6.4 Aurobindo Pharma Carbapenem-Based Antibiotics Product Portfolio

6.6.5 Aurobindo Pharma Recent Developments/Updates

6.7 Daewoong Pharmaceutical

6.7.1 Daewoong Pharmaceutical Company Information

6.7.2 Daewoong Pharmaceutical Description and Business Overview

6.7.3 Daewoong Pharmaceutical Carbapenem-Based Antibiotics Sales, Revenue, and Gross Margin (2021–2026)

6.7.4 Daewoong Pharmaceutical Carbapenem-Based Antibiotics Product Portfolio

6.7.5 Daewoong Pharmaceutical Recent Developments/Updates

6.8 ACS Dobfar

6.8.1 ACS Dobfar Company Information

6.8.2 ACS Dobfar Description and Business Overview

6.8.3 ACS Dobfar Carbapenem-Based Antibiotics Sales, Revenue, and Gross Margin (2021–2026)

6.8.4 ACS Dobfar Carbapenem-Based Antibiotics Product Portfolio

6.8.5 ACS Dobfar Recent Developments/Updates

6.9 Fresenius

6.9.1 Fresenius Company Information

6.9.2 Fresenius Description and Business Overview

6.9.3 Fresenius Carbapenem-Based Antibiotics Sales, Revenue, and Gross Margin (2021–2026)

6.9.4 Fresenius Carbapenem-Based Antibiotics Product Portfolio

6.9.5 Fresenius Recent Developments/Updates

6.10 Sun Pharmaceutical

6.10.1 Sun Pharmaceutical Company Information

6.10.2 Sun Pharmaceutical Description and Business Overview

6.10.3 Sun Pharmaceutical Carbapenem-Based Antibiotics Sales, Revenue, and Gross Margin (2021–2026)

6.10.4 Sun Pharmaceutical Carbapenem-Based Antibiotics Product Portfolio

6.10.5 Sun Pharmaceutical Recent Developments/Updates

6.11 Hikma Pharmaceuticals

6.11.1 Hikma Pharmaceuticals Company Information

6.11.2 Hikma Pharmaceuticals Description and Business Overview

6.11.3 Hikma Pharmaceuticals Carbapenem-Based Antibiotics Sales, Revenue, and Gross Margin (2021–2026)

6.11.4 Hikma Pharmaceuticals Carbapenem-Based Antibiotics Product Portfolio

6.11.5 Hikma Pharmaceuticals Recent Developments/Updates

6.12 CSPC Pharmaceutical Group

6.12.1 CSPC Pharmaceutical Group Company Information

6.12.2 CSPC Pharmaceutical Group Description and Business Overview

6.12.3 CSPC Pharmaceutical Group Carbapenem-Based Antibiotics Sales, Revenue, and Gross Margin (2021–2026)

6.12.4 CSPC Pharmaceutical Group Carbapenem-Based Antibiotics Product Portfolio

6.12.5 CSPC Pharmaceutical Group Recent Developments/Updates

6.13 Shenzhen Haibin Pharmaceutical

6.13.1 Shenzhen Haibin Pharmaceutical Company Information

6.13.2 Shenzhen Haibin Pharmaceutical Description and Business Overview

6.13.3 Shenzhen Haibin Pharmaceutical Carbapenem-Based Antibiotics Sales, Revenue, and Gross Margin (2021–2026)

6.13.4 Shenzhen Haibin Pharmaceutical Carbapenem-Based Antibiotics Product Portfolio

6.13.5 Shenzhen Haibin Pharmaceutical Recent Developments/Updates

6.14 JW Pharmaceutical

6.14.1 JW Pharmaceutical Company Information

6.14.2 JW Pharmaceutical Description and Business Overview

6.14.3 JW Pharmaceutical Carbapenem-Based Antibiotics Sales, Revenue, and Gross Margin (2021–2026)

6.14.4 JW Pharmaceutical Carbapenem-Based Antibiotics Product Portfolio

6.14.5 JW Pharmaceutical Recent Developments/Updates

6.15 Taiwan Biotech

6.15.1 Taiwan Biotech Company Information

6.15.2 Taiwan Biotech Description and Business Overview

6.15.3 Taiwan Biotech Carbapenem-Based Antibiotics Sales, Revenue, and Gross Margin (2021–2026)

6.15.4 Taiwan Biotech Carbapenem-Based Antibiotics Product Portfolio

6.15.5 Taiwan Biotech Recent Developments/Updates

6.16 Zhuhai United Laboratories

6.16.1 Zhuhai United Laboratories Company Information

6.16.2 Zhuhai United Laboratories Description and Business Overview

6.16.3 Zhuhai United Laboratories Carbapenem-Based Antibiotics Sales, Revenue, and Gross Margin (2021–2026)

6.16.4 Zhuhai United Laboratories Carbapenem-Based Antibiotics Product Portfolio

6.16.5 Zhuhai United Laboratories Recent Developments/Updates

6.17 Endo International

6.17.1 Endo International Company Information

6.17.2 Endo International Description and Business Overview

6.17.3 Endo International Carbapenem-Based Antibiotics Sales, Revenue, and Gross Margin (2021–2026)

6.17.4 Endo International Carbapenem-Based Antibiotics Product Portfolio

6.17.5 Endo International Recent Developments/Updates

6.18 Apotex

6.18.1 Apotex Company Information

6.18.2 Apotex Description and Business Overview

6.18.3 Apotex Carbapenem-Based Antibiotics Sales, Revenue, and Gross Margin (2021–2026)

6.18.4 Apotex Carbapenem-Based Antibiotics Product Portfolio

6.18.5 Apotex Recent Developments/Updates

6.19 Dr Reddy's Laboratories

6.19.1 Dr Reddy's Laboratories Company Information

6.19.2 Dr Reddy's Laboratories Description and Business Overview

6.19.3 Dr Reddy's Laboratories Carbapenem-Based Antibiotics Sales, Revenue, and Gross Margin (2021–2026)

6.19.4 Dr Reddy's Laboratories Carbapenem-Based Antibiotics Product Portfolio

6.19.5 Dr Reddy's Laboratories Recent Developments/Updates

6.20 Chongqing Shenghuaxi Pharm

6.20.1 Chongqing Shenghuaxi Pharm Company Information

6.20.2 Chongqing Shenghuaxi Pharm Description and Business Overview

6.20.3 Chongqing Shenghuaxi Pharm Carbapenem-Based Antibiotics Sales, Revenue, and Gross Margin (2021–2026)

6.20.4 Chongqing Shenghuaxi Pharm Carbapenem-Based Antibiotics Product Portfolio

6.20.5 Chongqing Shenghuaxi Pharm Recent Developments/Updates

7.1 Carbapenem-Based Antibiotics Industry Chain Analysis

7.2 Carbapenem-Based Antibiotics Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Carbapenem-Based Antibiotics Production Mode & Process Analysis

7.4 Carbapenem-Based Antibiotics Sales and Marketing

7.4.1 Carbapenem-Based Antibiotics Sales Channels

7.4.2 Carbapenem-Based Antibiotics Distributors

7.5 Carbapenem-Based Antibiotics Customer Analysis

8.1 Carbapenem-Based Antibiotics Industry Trends

8.2 Carbapenem-Based Antibiotics Market Drivers

8.3 Carbapenem-Based Antibiotics Market Challenges

8.4 Carbapenem-Based Antibiotics Market Restraints

8.5 Impact of U.S. Tariffs

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

List of Tables

 Table 1. Global Carbapenem-Based Antibiotics Market Value by Type (US$ Million), 2025 vs 2032

 Table 2. Global Carbapenem-Based Antibiotics Market Value by Dosage Form (US$ Million), 2025 vs 2032

 Table 3. Global Carbapenem-Based Antibiotics Market Value by Clinical Indication (US$ Million), 2025 vs 2032

 Table 4. Global Carbapenem-Based Antibiotics Market Value by Application (US$ Million), 2025 vs 2032

 Table 5. Global Carbapenem-Based Antibiotics Market Competitive Situation by Manufacturers in 2025

 Table 6. Global Carbapenem-Based Antibiotics Sales (K Units) of Key Manufacturers (2021–2026)

 Table 7. Global Carbapenem-Based Antibiotics Sales Market Share by Manufacturers (2021–2026)

 Table 8. Global Carbapenem-Based Antibiotics Revenue (US$ Million) by Manufacturers (2021–2026)

 Table 9. Global Carbapenem-Based Antibiotics Revenue Share by Manufacturers (2021–2026)

 Table 10. Global Market Carbapenem-Based Antibiotics Average Price (US$/Unit) of Key Manufacturers (2021–2026)

 Table 11. Global Key Players of Carbapenem-Based Antibiotics, Industry Ranking, 2023 vs 2024 vs 2025

 Table 12. Global Key Manufacturers of Carbapenem-Based Antibiotics, Manufacturing Sites and Headquarters

 Table 13. Global Key Manufacturers of Carbapenem-Based Antibiotics, Product Types and Applications

 Table 14. Global Key Manufacturers of Carbapenem-Based Antibiotics, Date of Entry into the Industry

 Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

 Table 16. Global Carbapenem-Based Antibiotics Companies by Tier (Tier 1, Tier 2, Tier 3), based on Carbapenem-Based Antibiotics Revenue, 2025

 Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans

 Table 18. Global Carbapenem-Based Antibiotics Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

 Table 19. Global Carbapenem-Based Antibiotics Sales by Region (K Units), 2021–2026

 Table 20. Global Carbapenem-Based Antibiotics Sales Market Share by Region (2021–2026)

 Table 21. Global Carbapenem-Based Antibiotics Sales by Region (K Units), 2027–2032

 Table 22. Global Carbapenem-Based Antibiotics Sales Market Share by Region (2027–2032)

 Table 23. Global Carbapenem-Based Antibiotics Revenue by Region (US$ Million), 2021–2026

 Table 24. Global Carbapenem-Based Antibiotics Revenue Market Share by Region (2021–2026)

 Table 25. Global Carbapenem-Based Antibiotics Revenue by Region (US$ Million), 2027–2032

 Table 26. Global Carbapenem-Based Antibiotics Revenue Market Share by Region (2027–2032)

 Table 27. North America Carbapenem-Based Antibiotics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

 Table 28. North America Carbapenem-Based Antibiotics Sales by Country (K Units), 2021–2026

 Table 29. North America Carbapenem-Based Antibiotics Sales by Country (K Units), 2027–2032

 Table 30. North America Carbapenem-Based Antibiotics Revenue by Country (US$ Million), 2021–2026

 Table 31. North America Carbapenem-Based Antibiotics Revenue by Country (US$ Million), 2027–2032

 Table 32. Europe Carbapenem-Based Antibiotics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

 Table 33. Europe Carbapenem-Based Antibiotics Sales by Country (K Units), 2021–2026

 Table 34. Europe Carbapenem-Based Antibiotics Sales by Country (K Units), 2027–2032

 Table 35. Europe Carbapenem-Based Antibiotics Revenue by Country (US$ Million), 2021–2026

 Table 36. Europe Carbapenem-Based Antibiotics Revenue by Country (US$ Million), 2027–2032

 Table 37. Asia Pacific Carbapenem-Based Antibiotics Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)

 Table 38. Asia Pacific Carbapenem-Based Antibiotics Sales by Region (K Units), 2021–2026

 Table 39. Asia Pacific Carbapenem-Based Antibiotics Sales by Region (K Units), 2027–2032

 Table 40. Asia Pacific Carbapenem-Based Antibiotics Revenue by Region (US$ Million), 2021–2026

 Table 41. Asia Pacific Carbapenem-Based Antibiotics Revenue by Region (US$ Million), 2027–2032

 Table 42. Latin America Carbapenem-Based Antibiotics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

 Table 43. Latin America Carbapenem-Based Antibiotics Sales by Country (K Units), 2021–2026

 Table 44. Latin America Carbapenem-Based Antibiotics Sales by Country (K Units), 2027–2032

 Table 45. Latin America Carbapenem-Based Antibiotics Revenue by Country (US$ Million), 2021–2026

 Table 46. Latin America Carbapenem-Based Antibiotics Revenue by Country (US$ Million), 2027–2032

 Table 47. Middle East and Africa Carbapenem-Based Antibiotics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

 Table 48. Middle East and Africa Carbapenem-Based Antibiotics Sales by Country (K Units), 2021–2026

 Table 49. Middle East and Africa Carbapenem-Based Antibiotics Sales by Country (K Units), 2027–2032

 Table 50. Middle East and Africa Carbapenem-Based Antibiotics Revenue by Country (US$ Million), 2021–2026

 Table 51. Middle East and Africa Carbapenem-Based Antibiotics Revenue by Country (US$ Million), 2027–2032

 Table 52. Global Carbapenem-Based Antibiotics Sales (K Units) by Type (2021–2026)

 Table 53. Global Carbapenem-Based Antibiotics Sales (K Units) by Type (2027–2032)

 Table 54. Global Carbapenem-Based Antibiotics Sales Market Share by Type (2021–2026)

 Table 55. Global Carbapenem-Based Antibiotics Sales Market Share by Type (2027–2032)

 Table 56. Global Carbapenem-Based Antibiotics Revenue (US$ Million) by Type (2021–2026)

 Table 57. Global Carbapenem-Based Antibiotics Revenue (US$ Million) by Type (2027–2032)

 Table 58. Global Carbapenem-Based Antibiotics Revenue Market Share by Type (2021–2026)

 Table 59. Global Carbapenem-Based Antibiotics Revenue Market Share by Type (2027–2032)

 Table 60. Global Carbapenem-Based Antibiotics Price (US$/Unit) by Type (2021–2026)

 Table 61. Global Carbapenem-Based Antibiotics Price (US$/Unit) by Type (2027–2032)

 Table 62. Global Carbapenem-Based Antibiotics Sales (K Units) by Application (2021–2026)

 Table 63. Global Carbapenem-Based Antibiotics Sales (K Units) by Application (2027–2032)

 Table 64. Global Carbapenem-Based Antibiotics Sales Market Share by Application (2021–2026)

 Table 65. Global Carbapenem-Based Antibiotics Sales Market Share by Application (2027–2032)

 Table 66. Global Carbapenem-Based Antibiotics Revenue (US$ Million) by Application (2021–2026)

 Table 67. Global Carbapenem-Based Antibiotics Revenue (US$ Million) by Application (2027–2032)

 Table 68. Global Carbapenem-Based Antibiotics Revenue Market Share by Application (2021–2026)

 Table 69. Global Carbapenem-Based Antibiotics Revenue Market Share by Application (2027–2032)

 Table 70. Global Carbapenem-Based Antibiotics Price (US$/Unit) by Application (2021–2026)

 Table 71. Global Carbapenem-Based Antibiotics Price (US$/Unit) by Application (2027–2032)

 Table 72. Gland Pharma Company Information

 Table 73. Gland Pharma Description and Business Overview

 Table 74. Gland Pharma Carbapenem-Based Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

 Table 75. Gland Pharma Carbapenem-Based Antibiotics Product

 Table 76. Gland Pharma Recent Developments/Updates

 Table 77. Merck Company Information

 Table 78. Merck Description and Business Overview

 Table 79. Merck Carbapenem-Based Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

 Table 80. Merck Carbapenem-Based Antibiotics Product

 Table 81. Merck Recent Developments/Updates

 Table 82. Savior Lifetec Company Information

 Table 83. Savior Lifetec Description and Business Overview

 Table 84. Savior Lifetec Carbapenem-Based Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

 Table 85. Savior Lifetec Carbapenem-Based Antibiotics Product

 Table 86. Savior Lifetec Recent Developments/Updates

 Table 87. Sumitomo Pharma Company Information

 Table 88. Sumitomo Pharma Description and Business Overview

 Table 89. Sumitomo Pharma Carbapenem-Based Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

 Table 90. Sumitomo Pharma Carbapenem-Based Antibiotics Product

 Table 91. Sumitomo Pharma Recent Developments/Updates

 Table 92. Pfizer Company Information

 Table 93. Pfizer Description and Business Overview

 Table 94. Pfizer Carbapenem-Based Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

 Table 95. Pfizer Carbapenem-Based Antibiotics Product

 Table 96. Pfizer Recent Developments/Updates

 Table 97. Aurobindo Pharma Company Information

 Table 98. Aurobindo Pharma Description and Business Overview

 Table 99. Aurobindo Pharma Carbapenem-Based Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

 Table 100. Aurobindo Pharma Carbapenem-Based Antibiotics Product

 Table 101. Aurobindo Pharma Recent Developments/Updates

 Table 102. Daewoong Pharmaceutical Company Information

 Table 103. Daewoong Pharmaceutical Description and Business Overview

 Table 104. Daewoong Pharmaceutical Carbapenem-Based Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

 Table 105. Daewoong Pharmaceutical Carbapenem-Based Antibiotics Product

 Table 106. Daewoong Pharmaceutical Recent Developments/Updates

 Table 107. ACS Dobfar Company Information

 Table 108. ACS Dobfar Description and Business Overview

 Table 109. ACS Dobfar Carbapenem-Based Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

 Table 110. ACS Dobfar Carbapenem-Based Antibiotics Product

 Table 111. ACS Dobfar Recent Developments/Updates

 Table 112. Fresenius Company Information

 Table 113. Fresenius Description and Business Overview

 Table 114. Fresenius Carbapenem-Based Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

 Table 115. Fresenius Carbapenem-Based Antibiotics Product

 Table 116. Fresenius Recent Developments/Updates

 Table 117. Sun Pharmaceutical Company Information

 Table 118. Sun Pharmaceutical Description and Business Overview

 Table 119. Sun Pharmaceutical Carbapenem-Based Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

 Table 120. Sun Pharmaceutical Carbapenem-Based Antibiotics Product

 Table 121. Sun Pharmaceutical Recent Developments/Updates

 Table 122. Hikma Pharmaceuticals Company Information

 Table 123. Hikma Pharmaceuticals Description and Business Overview

 Table 124. Hikma Pharmaceuticals Carbapenem-Based Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

 Table 125. Hikma Pharmaceuticals Carbapenem-Based Antibiotics Product

 Table 126. Hikma Pharmaceuticals Recent Developments/Updates

 Table 127. CSPC Pharmaceutical Group Company Information

 Table 128. CSPC Pharmaceutical Group Description and Business Overview

 Table 129. CSPC Pharmaceutical Group Carbapenem-Based Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

 Table 130. CSPC Pharmaceutical Group Carbapenem-Based Antibiotics Product

 Table 131. CSPC Pharmaceutical Group Recent Developments/Updates

 Table 132. Shenzhen Haibin Pharmaceutical Company Information

 Table 133. Shenzhen Haibin Pharmaceutical Description and Business Overview

 Table 134. Shenzhen Haibin Pharmaceutical Carbapenem-Based Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

 Table 135. Shenzhen Haibin Pharmaceutical Carbapenem-Based Antibiotics Product

 Table 136. Shenzhen Haibin Pharmaceutical Recent Developments/Updates

 Table 137. JW Pharmaceutical Company Information

 Table 138. JW Pharmaceutical Description and Business Overview

 Table 139. JW Pharmaceutical Carbapenem-Based Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

 Table 140. JW Pharmaceutical Carbapenem-Based Antibiotics Product

 Table 141. JW Pharmaceutical Recent Developments/Updates

 Table 142. Taiwan Biotech Company Information

 Table 143. Taiwan Biotech Description and Business Overview

 Table 144. Taiwan Biotech Carbapenem-Based Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

 Table 145. Taiwan Biotech Carbapenem-Based Antibiotics Product

 Table 146. Taiwan Biotech Recent Developments/Updates

 Table 147. Zhuhai United Laboratories Company Information

 Table 148. Zhuhai United Laboratories Description and Business Overview

 Table 149. Zhuhai United Laboratories Carbapenem-Based Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

 Table 150. Zhuhai United Laboratories Carbapenem-Based Antibiotics Product

 Table 151. Zhuhai United Laboratories Recent Developments/Updates

 Table 152. Endo International Company Information

 Table 153. Endo International Description and Business Overview

 Table 154. Endo International Carbapenem-Based Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

 Table 155. Endo International Carbapenem-Based Antibiotics Product

 Table 156. Endo International Recent Developments/Updates

 Table 157. Apotex Company Information

 Table 158. Apotex Description and Business Overview

 Table 159. Apotex Carbapenem-Based Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

 Table 160. Apotex Carbapenem-Based Antibiotics Product

 Table 161. Apotex Recent Developments/Updates

 Table 162. Dr Reddy's Laboratories Company Information

 Table 163. Dr Reddy's Laboratories Description and Business Overview

 Table 164. Dr Reddy's Laboratories Carbapenem-Based Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

 Table 165. Dr Reddy's Laboratories Carbapenem-Based Antibiotics Product

 Table 166. Dr Reddy's Laboratories Recent Developments/Updates

 Table 167. Chongqing Shenghuaxi Pharm Company Information

 Table 168. Chongqing Shenghuaxi Pharm Description and Business Overview

 Table 169. Chongqing Shenghuaxi Pharm Carbapenem-Based Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

 Table 170. Chongqing Shenghuaxi Pharm Carbapenem-Based Antibiotics Product

 Table 171. Chongqing Shenghuaxi Pharm Recent Developments/Updates

 Table 172. Key Raw Materials Lists

 Table 173. Raw Materials Key Suppliers Lists

 Table 174. Carbapenem-Based Antibiotics Distributors List

 Table 175. Carbapenem-Based Antibiotics Customers List

 Table 176. Carbapenem-Based Antibiotics Market Trends

 Table 177. Carbapenem-Based Antibiotics Market Drivers

 Table 178. Carbapenem-Based Antibiotics Market Challenges

 Table 179. Carbapenem-Based Antibiotics Market Restraints

 Table 180. Research Programs/Design for This Report

 Table 181. Key Data Information from Secondary Sources

 Table 182. Key Data Information from Primary Sources

 Table 183. Authors List of This Report

List of Figures

 Figure 1. Product Picture of Carbapenem-Based Antibiotics

 Figure 2. Global Carbapenem-Based Antibiotics Market Value by Type (US$ Million), 2021–2032

 Figure 3. Global Carbapenem-Based Antibiotics Market Share by Type: 2025 & 2032

 Figure 4. Meropenem Product Picture

 Figure 5. Imipenem Product Picture

 Figure 6. Ertapenem Product Picture

 Figure 7. Doripenem Product Picture

 Figure 8. Others Product Picture

 Figure 9. Global Carbapenem-Based Antibiotics Market Value by Dosage Form (US$ Million), 2021–2032

 Figure 10. Global Carbapenem-Based Antibiotics Market Share by Dosage Form: 2025 vs 2032

 Figure 11. Sterile Powder for Injection Product Picture

 Figure 12. Ready-to-use or Premixed Injection Product Picture

 Figure 13. Others Product Picture

 Figure 14. Global Carbapenem-Based Antibiotics Market Value by Clinical Indication (US$ Million), 2021–2032

 Figure 15. Global Carbapenem-Based Antibiotics Market Share by Clinical Indication: 2025 vs 2032

 Figure 16. Severe Hospital-acquired Infections Product Picture

 Figure 17. Drug-resistant Bacterial Infections Product Picture

 Figure 18. Others Product Picture

 Figure 19. Global Carbapenem-Based Antibiotics Market Value by Application (US$ Million), 2021–2032

 Figure 20. Global Carbapenem-Based Antibiotics Market Share by Application: 2025 & 2032

 Figure 21. Hospital

 Figure 22. Clinic

 Figure 23. Others

 Figure 24. Global Carbapenem-Based Antibiotics Revenue, (US$ Million), 2021 vs 2025 vs 2032

 Figure 25. Global Carbapenem-Based Antibiotics Market Size (US$ Million), 2021–2032

 Figure 26. Global Carbapenem-Based Antibiotics Sales (K Units), 2021–2032

 Figure 27. Global Carbapenem-Based Antibiotics Average Price (US$/Unit), 2021–2032

 Figure 28. Carbapenem-Based Antibiotics Report Years Considered

 Figure 29. Carbapenem-Based Antibiotics Sales Share by Manufacturers in 2025

 Figure 30. Global Carbapenem-Based Antibiotics Revenue Share by Manufacturers in 2025

 Figure 31. Top 5 and Top 10 Global Carbapenem-Based Antibiotics Players: Market Share by Revenue in Carbapenem-Based Antibiotics in 2025

 Figure 32. Carbapenem-Based Antibiotics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

 Figure 33. Global Carbapenem-Based Antibiotics Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

 Figure 34. North America Carbapenem-Based Antibiotics Sales Market Share by Country (2021–2032)

 Figure 35. North America Carbapenem-Based Antibiotics Revenue Market Share by Country (2021–2032)

 Figure 36. U.S. Carbapenem-Based Antibiotics Revenue Growth Rate (US$ Million), 2021–2032

 Figure 37. Canada Carbapenem-Based Antibiotics Revenue Growth Rate (US$ Million), 2021–2032

 Figure 38. Europe Carbapenem-Based Antibiotics Sales Market Share by Country (2021–2032)

 Figure 39. Europe Carbapenem-Based Antibiotics Revenue Market Share by Country (2021–2032)

 Figure 40. Germany Carbapenem-Based Antibiotics Revenue Growth Rate (US$ Million), 2021–2032

 Figure 41. France Carbapenem-Based Antibiotics Revenue Growth Rate (US$ Million), 2021–2032

 Figure 42. U.K. Carbapenem-Based Antibiotics Revenue Growth Rate (US$ Million), 2021–2032

 Figure 43. Italy Carbapenem-Based Antibiotics Revenue Growth Rate (US$ Million), 2021–2032

 Figure 44. Russia Carbapenem-Based Antibiotics Revenue Growth Rate (US$ Million), 2021–2032

 Figure 45. Asia Pacific Carbapenem-Based Antibiotics Sales Market Share by Region (2021–2032)

 Figure 46. Asia Pacific Carbapenem-Based Antibiotics Revenue Market Share by Region (2021–2032)

 Figure 47. China Carbapenem-Based Antibiotics Revenue Growth Rate (US$ Million), 2021–2032

 Figure 48. Japan Carbapenem-Based Antibiotics Revenue Growth Rate (US$ Million), 2021–2032

 Figure 49. South Korea Carbapenem-Based Antibiotics Revenue Growth Rate (US$ Million), 2021–2032

 Figure 50. India Carbapenem-Based Antibiotics Revenue Growth Rate (US$ Million), 2021–2032

 Figure 51. Australia Carbapenem-Based Antibiotics Revenue Growth Rate (US$ Million), 2021–2032

 Figure 52. Taiwan Carbapenem-Based Antibiotics Revenue Growth Rate (US$ Million), 2021–2032

 Figure 53. Indonesia Carbapenem-Based Antibiotics Revenue Growth Rate (US$ Million), 2021–2032

 Figure 54. Thailand Carbapenem-Based Antibiotics Revenue Growth Rate (US$ Million), 2021–2032

 Figure 55. Malaysia Carbapenem-Based Antibiotics Revenue Growth Rate (US$ Million), 2021–2032

 Figure 56. Philippines Carbapenem-Based Antibiotics Revenue Growth Rate (US$ Million), 2021–2032

 Figure 57. Latin America Carbapenem-Based Antibiotics Sales Market Share by Country (2021–2032)

 Figure 58. Latin America Carbapenem-Based Antibiotics Revenue Market Share by Country (2021–2032)

 Figure 59. Mexico Carbapenem-Based Antibiotics Revenue Growth Rate (US$ Million), 2021–2032

 Figure 60. Brazil Carbapenem-Based Antibiotics Revenue Growth Rate (US$ Million), 2021–2032

 Figure 61. Argentina Carbapenem-Based Antibiotics Revenue Growth Rate (US$ Million), 2021–2032

 Figure 62. Middle East and Africa Carbapenem-Based Antibiotics Sales Market Share by Country (2021–2032)

 Figure 63. Middle East and Africa Carbapenem-Based Antibiotics Revenue Market Share by Country (2021–2032)

 Figure 64. Turkey Carbapenem-Based Antibiotics Revenue Growth Rate (US$ Million), 2021–2032

 Figure 65. Saudi Arabia Carbapenem-Based Antibiotics Revenue Growth Rate (US$ Million), 2021–2032

 Figure 66. U.A.E Carbapenem-Based Antibiotics Revenue Growth Rate (US$ Million), 2021–2032

 Figure 67. Global Sales Market Share of Carbapenem-Based Antibiotics by Type (2021–2032)

 Figure 68. Global Revenue Market Share of Carbapenem-Based Antibiotics by Type (2021–2032)

 Figure 69. Global Carbapenem-Based Antibiotics Price (US$/Unit) by Type (2021–2032)

 Figure 70. Global Sales Market Share of Carbapenem-Based Antibiotics by Application (2021–2032)

 Figure 71. Global Revenue Market Share of Carbapenem-Based Antibiotics by Application (2021–2032)

 Figure 72. Global Carbapenem-Based Antibiotics Price (US$/Unit) by Application (2021–2032)

 Figure 73. Carbapenem-Based Antibiotics Value Chain

 Figure 74. Channels of Distribution (Direct Vs Distribution)

 Figure 75. Bottom-up and Top-down Approaches for This Report

 Figure 76. Data Triangulation

 Figure 77. Key Executives Interviewed